WALL STREET TRADER
BIOSIG TECHNOLOGIES INC
THESE SHARES IN BREAKOUT TERRITORY
BUY TARGET $5.50
These shares have broken above a $2.50 base and is now in breakout territory. We feel these shares can now challenge the triple top at $5.50 We urge all serious investors to place these shares on their BUY LIST
Five reasons BSGM is ready to move significantly higher in the coming months and to all time highs in the next 12-15 months
o Pandemic slowed down sales but hospitals are starting to spend again and PURE EP is now proven to provide better signals in ablations of Afib and deadly ventricular tachycardia allowing more efficient & quicker ablations with Drs having better visual evidence as to where to target lesions during the procedure. Drs at HRS said PURE EP likely saved lives during actual VT patient procedures. Remember ablations are one of the most profitable procedures in most hospitals and improved efficiency makes them even more profitable.
o Hospitals and electrophysiologists loved the trial results and visual evidence of better PURE EP signals but many administrators wanted independent peer reviewed publication of trial data before finalizing purchases and now they have that :
o Universal praise of the PURE EP system by participants of the BioSig events at the Annual Boston Heart Rhythm Society Symposium this summer including multiple successful meetings with BioSig and potential partners. Presentations praising PURE EP technology made by 4 of the industry’s top 10 KOL’s including #1 Dr Natalie for TCAI and others from The Mayo Clinic and UPENN have significantly increased sales and partnership interest.
o Medtronic’s lack of halt of it’s phase 3 renal denervation trial for hypertension almost certainly increases there already strong interest in BSGM’s renal ablation signal technology.
o Several significant licensed technology ( In addition to the core ablation and renal ablation work underway) obtained years ago from The Mayo Clinic have been worked on for years now and should be ready for prime time likely next year where the full worth of BioSig’s strong patent estate and intellectual property extending into AI and other areas will finally be fully understood by investors.
All in all we see the potential for a significant reversal of BioSig stock especially coming off tax loss indiscriminate selling by funds that have an October 31 year end that is now behind us. Remember ablation and the electrophysiology lab is the most profitable area of most hospitals and having a technology that allows better and quicker ablations with procedural growth happening concurrently because of aging demographics and better diagnosis technology is a game changer in the industry. With now peer reviewed publication fundamentals and the best HRS meeting feedback In the company’s history, it’s time to consider purchase of BSGM.
Plum Tree Consulting LLC
Cell: (516) 455-7662
BioSig Increases Case Volume Estimates
The Company reports increased adoption and commercial activity of its signal processing technology for arrhythmia care
Westport, CT, Nov. 01, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it exceeded its procedural target of 1500 patient cases in 2021.
As of October 21, 2021, the PURE EP(tm) System had been used in over 1560 patient cases by 71 physicians, up from 1000 cases in June 2021, when the procedural guidance was raised amid increased technology usage in elective procedures. As the adoption of the technology increases and the COVID-19 hospitalization rates continue to decline, the Company intends to complete between 1700-1800 procedures by the end of 2021.
“We are seeing increased utilization of PURE EP(tm) in the 13 hospitals we are currently working in. Physicians recognize value both clinically and economically or they would not be increasing their usage. Hospitals are rapidly scaling their elective procedures and thus we are now seeing increased case volumes and commercial activity,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
Clinical data acquired by the PURE EP(tm) System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library . Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(tm) signals over conventional sources.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals ( www.biosig.com ).
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Plum Tree Consulting LLC
Cell: (516) 455-7662
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision Writer is not paid nor holds shares